studies

lung cancer : non small cell (NSCLC), ... vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsISEL, 2005 0.89 [0.77; 1.02] 0.89[0.77; 1.02]ISEL, 200510%1,692NAnot evaluable objective responses (ORR)detailed resultsISEL, 2005 7.28 [3.12; 17.00] 7.28[3.12; 17.00]ISEL, 200510%1,439NAnot evaluable AE (any grade)detailed resultsISEL, 2005 1.86 [1.47; 2.35] 1.86[1.47; 2.35]ISEL, 200510%1,688NAnot evaluable AE (grade 3-4)detailed resultsISEL, 2005 1.16 [0.92; 1.45] 1.16[0.92; 1.45]ISEL, 200510%1,688NAnot evaluable AE leading to death (grade 5)detailed resultsISEL, 2005 1.28 [0.78; 2.13] 1.28[0.78; 2.13]ISEL, 200510%1,688NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsISEL, 2005 2.62 [1.36; 5.04] 2.62[1.36; 5.04]ISEL, 200510%1,688NAnot evaluable0.510.01.0relative treatment effectwww.metaEvidence.org2024-07-03 17:17 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334 - treatments: 971

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons